Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $65.33 USD
Change Today -0.98 / -1.48%
Volume 2.1M
ISIS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Open
$65.20
Previous Close
$66.31
Day High
$66.20
Day Low
$64.61
52 Week High
03/20/15 - $77.80
52 Week Low
05/9/14 - $22.25
Market Cap
7.8B
Average Volume 10 Days
2.1M
EPS TTM
$-0.22
Shares Outstanding
119.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISIS PHARMACEUTICALS INC (ISIS)

isis pharmaceuticals inc (ISIS) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 38 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, which include neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., OncoGenex Technologies Inc., Janssen Biotech, Inc., and Atlantic Pharmaceuticals Limited. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

390 Employees
Last Reported Date: 03/2/15
Founded in 1989

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $584.6K
Chief Operating Officer, Corporate Secretary,...
Total Annual Compensation: $1.1M
Senior Vice President of Development
Total Annual Compensation: $636.1K
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Compensation as of Fiscal Year 2014.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:40 AM

Isis Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 08:40 AM. Venue: Westin Grand Central Hotel, New York, New York, United States.

Isis Pharmaceuticals, Inc. Reports Positive Phase 1 Data on Isis-ANGPTL3Rx

Isis Pharmaceuticals, Inc. announced positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93% with a mean reduction of up to 84% from baseline (prdEuropean Atherosclerosis Society in Glasgow, United Kingdom). The Phase 1 study of ISIS-ANGPTL3Rx was a blinded, placebo-controlled, dose-escalation study in healthy volunteers. The study was designed to assess the safety, tolerability and pharmacokinetics of ISIS-ANGPTL3Rx. ISIS-ANGPTL3Rx was evaluated in single and multiple doses ranging from 50 mg per week up to 400 mg per week for the single dose and 100 mg per week up to 400 mg per week for the multiple dose. In this study, ISIS-ANGPTL3Rx was generally well tolerated. ISIS-ANGPTL3Rx is an antisense drug designed to reduce ANGPTL3. ANGPTL3 is produced in the liver and regulates lipid, glucose and energy metabolism. In preclinical studies, antisense inhibition of ANGPTL3 resulted in robust reductions of multiple lipid parameters, including total-cholesterol, and triglycerides. ISIS-ANGPTL3Rx is part of Isis' lipid franchise and, as such, Akcea Therapeutics is responsible for developing ISIS-ANGPTL3Rx.

Isis Pharmaceuticals Earns $15 Million from GSK for Advancing ISIS-TTR Rx

Isis Pharmaceuticals, Inc. announced that it has earned a $15 million milestone payment from GSK related to advancing the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP). ISIS-TTRRx is an antisense drug Isis is developing with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $60 million in upfront and milestone payments for advancing ISIS-TTRRx. In addition, if GSK elects to exercise its option to exclusively license ISIS-TTRRx, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx. The Phase 2/3 study of ISIS-TTRRx is a randomized, double-blind, placebo-controlled, international study designed to support an application for marketing approval of ISIS-TTRRx in patients with FAP. The fifteen month study will measure the effects of ISIS-TTRRx on neurological dysfunction and on quality-of-life.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $65.33 USD -0.98

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $38.03 USD -0.64
Acorda Therapeutics Inc $34.49 USD -0.19
Aegerion Pharmaceuticals Inc $25.22 USD -0.83
Depomed Inc $25.97 USD -1.09
Regulus Therapeutics Inc $17.30 USD +0.12
View Industry Companies
 

Industry Analysis

ISIS

Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.1x
Price/Book 30.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 30.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit www.isispharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.